Degner, Detlef

[["dc.bibliographiccitation.firstpage","32"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","PSYCHOPHARMAKOTHERAPIE"],["dc.bibliographiccitation.lastpage","33"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Fiege, O."],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T08:47:19Z"],["dc.date.available","2018-11-07T08:47:19Z"],["dc.date.issued","2005"],["dc.identifier.isi","000227807100009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20924"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wissenschaftliche Verlag Mbh"],["dc.relation.issn","0944-6877"],["dc.title","Oculogyric crisis under aripiprazol in combination with fluoxetin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","560"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","573"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Toto, Sermin"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Frieling, Helge"],["dc.contributor.author","Maier, Hannah B"],["dc.contributor.author","Greil, Waldemar"],["dc.contributor.author","Cordes, Joachim"],["dc.contributor.author","Schmidt-Kraepelin, Christian"],["dc.contributor.author","Kasper, Siegfried"],["dc.contributor.author","Stübner, Susanne"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Druschky, Katrin"],["dc.contributor.author","Zindler, Tristan"],["dc.contributor.author","Neyazi, Alexandra"],["dc.date.accessioned","2020-12-10T18:19:17Z"],["dc.date.available","2020-12-10T18:19:17Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/ijnp/pyz037"],["dc.identifier.eissn","1469-5111"],["dc.identifier.issn","1461-1457"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16947"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75188"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/17087 but duplicate"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S84"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","S88"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Kropp, Silke"],["dc.contributor.author","Ziegenbein, M."],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Engel, Rolf R."],["dc.contributor.author","Degner, Detlef"],["dc.date.accessioned","2018-11-07T10:50:59Z"],["dc.date.available","2018-11-07T10:50:59Z"],["dc.date.issued","2004"],["dc.description.abstract","Within the drug safety program in psychiatry AMSP (Arzneimit-telsicherheit in der Psychiatrie), severe adverse drug reactions (ADRs) are assessed. Currently 35 psychiatric hospitals and departments are participating in detecting severe ADRs. This paper focuses on prolactin-dependent ADRs such as gynecomastia and galactorrhea due to psychotropic medications. Related to the number of patients Surveyed (422,562 from 1993 to 2000), these are rare events (0.03% or 35 cases). Imputed drugs were mostly antipsychotics, but antidepressants were also imputed in single cases. In the group of antipsychotics, relative frequencies of galactorrhea were highest for amisulpride and risperidone and corresponded to the degree of D2 binding. Galactorrhea assessed as \"severe\" was accompanied by distressing symptoms such as pain, tension, enlargement of breasts, or soaked clothing. The AMSP data contribute to the knowledge on endocrine ADRs by the large number of patients examined and help clinicians select the appropriate drug if their patients have been prone to for these ADRs in the past."],["dc.identifier.doi","10.1055/s-2004-815515"],["dc.identifier.isi","000221126100013"],["dc.identifier.pmid","15052519"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48781"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Galactorrhea due to psychotropic drugs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S79"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","S83"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Kropp, Silke"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Hauser, U."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Degner, Detlef"],["dc.date.accessioned","2018-11-07T10:50:59Z"],["dc.date.available","2018-11-07T10:50:59Z"],["dc.date.issued","2004"],["dc.description.abstract","The introduction of new antipsychotics has resulted in the availability of drugs with improved safety and tolerability as well as proven efficacy compared to the older antipsychotics. New compounds might show new or different adverse effects that arise in the post-marketing phase when a greater number of patients are treated. One goal of the drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) is the detection and description of severe, new, or rare adverse drug reactions (ADRs). Between 1993 and 2000, 122,562 patients were monitored in 35 psychiatric institutions, 86,349 patients of which received antipsychotics. Hyperglycemia related to antipsychotics was observed in association with only two compounds so far: A clozapine and olanzapine (clozapine 2 cases, olanzapine 7 cases). In 6 of 9 patients, weight gain preceded hyperglycemia. The relative frequency of these adverse drug related events was 0.013% for clozapine and 0.075% for olanzapine. The symptomatology included reversible hyperglycemia, worsening of existing diabetes, and new-onset diabetes. Control for glycemic dysregulation should be maintained in clinical practice with these drugs."],["dc.identifier.doi","10.1055/s-2004-815514"],["dc.identifier.isi","000221126100012"],["dc.identifier.pmid","15052518"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48780"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","255"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PSYCHOPHARMAKOTHERAPIE"],["dc.bibliographiccitation.lastpage","257"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Schmidt, Beate"],["dc.contributor.author","Ruether, Eckart"],["dc.contributor.author","Grohmann, Renate"],["dc.date.accessioned","2018-11-07T09:04:16Z"],["dc.date.available","2018-11-07T09:04:16Z"],["dc.date.issued","2006"],["dc.identifier.isi","000242404800010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25080"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wissenschaftliche Verlag Mbh"],["dc.relation.issn","0944-6877"],["dc.title","Excessive yawning under Sertralin und venlafaxin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S235"],["dc.bibliographiccitation.journal","Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","S236"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Bender, S."],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Grohmann, Renate"],["dc.date.accessioned","2018-11-07T10:43:36Z"],["dc.date.available","2018-11-07T10:43:36Z"],["dc.date.issued","2004"],["dc.identifier.isi","000225588000679"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47092"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.publisher.place","London"],["dc.relation.conference","Annual Meeting of the American-College-of-Neuropsychopharmacology"],["dc.relation.eventlocation","San Juan, PR"],["dc.relation.issn","0893-133X"],["dc.title","152.25 years of drug surveillance of psychiatry - The AMSP system, a multinational approach"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S39"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","S45"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Kropp, Silke"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Bender, S."],["dc.contributor.author","Engel, Rolf R."],["dc.contributor.author","Schmidt, Lutz G."],["dc.date.accessioned","2018-11-07T10:50:58Z"],["dc.date.available","2018-11-07T10:50:58Z"],["dc.date.issued","2004"],["dc.description.abstract","The goal of the German drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) is the assessment of severe or new adverse drug reactions (ADRs). Here we report on 53,042 of 122,562 patients treated with antidepressants who were monitored from 1993 to 2000 in 35 psychiatric hospitals in German-speaking countries. The overall incidence of severe ADRs of antidepressants was 1.4% of exposed patients; when only ADRs rated as probable or definite were considered, a rate of 0.9% in patients treated with antidepressants was observed. ADR rates were higher for TCAs (imputed in 1.0% of patients overall, respectively in 0.6% of patients when only ADs were imputed) and lower for MAO inhibitors and SSRIs (0.7% for both, respectively 0.3% and 0.4%). Within the TCA group there was a difference among clomipramine (2.1%, respectively 1.0%), amitriptyline (1.0%, respectively 0.6%), and doxepin or trimipramine (both 0.6%, respectively 0.3%). With regard to single SSRI, similar rates were observed for paroxetine (0.8%, respectively 0.5%) and for citalopram (0.7%, respectively 0.4%). Of the new dual-acting antidepressants, venlafaxine ranged at 0.9%, (respectively 0.5%) and mirtazapine at 0.6% (respectively 0.5%). In particular, TCAs were associated with known risks, such as toxic delirium, grand mal seizures, and hepatic (i.e., increased liver enzymes), urologic (i.e., urinary retention), allergic (i.e., exanthema), or cardiovascular (i.e., mainly orthostatic collapse) reactions. In SSRI-treated patients (non-delirious) psychic and neurological ADRs were most prominent, followed by gastrointestinal, dermatologic, and endocrinological/electrolyte reactions, with agitation, hyponatremia (probably as part of the SIADH syndrome and associated with severe neurologic or psychiatric symptoms in 64% of all cases), increased liver enzymes, nausea, and the serotonin syndrome as leading unwanted symptoms. Venlafaxine (in the immediate-release formulation) was associated with adverse CNS and somatic symptoms such as severe agitation, diarrhea, increased liver enzymes, hypertension, and hyponatremia. Mirtazapine was mostly connected with increased liver enzymes, cutaneous edema, and collapse, but with no case of significant hyponatremia. For drugs that potently inhibit serotonin uptake, serum sodium concentration should be controlled when applied in high-close therapy or in vulnerable patients."],["dc.identifier.doi","10.1055/s-2004-815509"],["dc.identifier.isi","000221126100007"],["dc.identifier.pmid","15052513"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48773"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","100"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","PSYCHOPHARMAKOTHERAPIE"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Stephan, P. L."],["dc.contributor.author","Jaquenoud-Sirot, E."],["dc.contributor.author","Thilmann, R."],["dc.contributor.author","Schmidt, B."],["dc.contributor.author","Wenda, B."],["dc.contributor.author","Grohmann, Renate"],["dc.date.accessioned","2018-11-07T11:05:58Z"],["dc.date.available","2018-11-07T11:05:58Z"],["dc.date.issued","2005"],["dc.identifier.isi","000230088400006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52192"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wissenschaftliche Verlag Mbh"],["dc.relation.issn","0944-6877"],["dc.title","Liver increase in value under psycho-prodrugs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","201"],["dc.bibliographiccitation.volume","230"],["dc.contributor.author","Koester, M."],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Engel, Rolf R."],["dc.contributor.author","Nitsche, M. A."],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Degner, Detlef"],["dc.date.accessioned","2018-11-07T09:18:14Z"],["dc.date.available","2018-11-07T09:18:14Z"],["dc.date.issued","2013"],["dc.description.abstract","There is little clinical data available about seizure rates in psychiatric inpatients, and there are no studies with reference data to the frequencies of antidepressant (AD) use for this important clinical population. This study investigates seizure rates during AD treatment in psychiatric inpatient settings, drawn from the transnational pharmacovigilance programme Arzneimittelsicherheit in der Psychiatrie (AMSP) in relation to the known frequencies of ADs used in the participating clinics. Comparisons are made to former publications and their limitations. Seventy-seven cases were identified with grand mal seizures (GMS) during AD treatment between 1993 and 2008, with a total number of 142,090 inpatients under surveillance treated with ADs in the participating hospitals. The calculated overall rate of reported seizures of patients during AD treatment in this collective is 0.05 % for ADs imputed alone or in combination with other psychotropic drug groups and 0.02 % when only ADs were given and held responsible for GMS. The patients receiving tri- or tetracyclic ADs (TCAs) had a 2-fold risk to develop a seizure as compared to the overall average rate in this sample. In 11 cases, there was only one AD imputed-the majority of these cases (9/11) were TCA. Monotherapy with selective serotonin reuptake inhibitors (SSRI) or dual serotonin and noradrenaline reuptake inhibitors (SNRI) were never imputed alone in this sample. The results of the study favour the assumption that SSRIs, noradrenergic and specific serotonergic antidepressants (NaSSA) and dual SNRI might be more appropriate than TCAs for the treatment of psychiatric patients with an enhanced seizure risk."],["dc.identifier.doi","10.1007/s00213-013-3281-8"],["dc.identifier.isi","000326117800002"],["dc.identifier.pmid","24068157"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28359"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-2072"],["dc.relation.issn","0033-3158"],["dc.title","Seizures during antidepressant treatment in psychiatric inpatients-results from the transnational pharmacovigilance project \"Arzneimittelsicherheit in der Psychiatrie\" (AMSP) 1993-2008"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],["dc.contributor.author","Köberle, Ursula"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Belz, Michael"],["dc.contributor.author","Greil, Waldemar"],["dc.contributor.author","Degner, Detlef"],["dc.date.accessioned","2022-10-04T10:22:00Z"],["dc.date.available","2022-10-04T10:22:00Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1007/s00103-022-03594-z"],["dc.identifier.pii","3594"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114560"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","1437-1588"],["dc.relation.issn","1436-9990"],["dc.rights.uri","https://www.springer.com/tdm"],["dc.title","Effekt der Rote-Hand-Briefe zu Citalopram und Escitalopram auf Verordnungszahlen bei der stationären Behandlung von Angsterkrankungen"],["dc.title.translated","Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]